Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Centro De Ingeniería Genética Y Biotecnología has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, showing a diverse prosecution landscape for a small number of actions.
The busiest examiner is GOTFREDSON, GAREN, who is responsible for 1 pending office action. This indicates that the 2 pending actions are split, with each of the 2 distinct examiners handling exactly one action.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOTFREDSON, GAREN | 1 | 40.0% | +28.0% |
| BUNNER, BRIDGET E | 1 | 64.5% | +19.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268118 | USE OF SYNTHETIC PEPTIDE FOR THE INDUCTION OF ANTITUMOR AND ANTIVIRAL IMMUNITY | GOTFREDSON, GAREN | 12d |
| 17918299 | PEPTIDE FOR THE TREATMENT OF CYTOKINE STORM SYNDROME | BUNNER, BRIDGET E | 16d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268118 | USE OF SYNTHETIC PEPTIDE FOR THE INDUCTION OF ANTITUMOR AND ANTIVIRAL IMMUNITY | GOTFREDSON, GAREN | 12d |
| 17918299 | PEPTIDE FOR THE TREATMENT OF CYTOKINE STORM SYNDROME | BUNNER, BRIDGET E | 16d |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18268118 | USE OF SYNTHETIC PEPTIDE FOR THE INDUCTION OF ANTITUMOR AND ANTIVIRAL IMMUNITY | GOTFREDSON, GAREN | 1619 | §102§103§112 | Non-Final OA | 12d | Pending | Jun 16, 2023 |
| 17918299 | PEPTIDE FOR THE TREATMENT OF CYTOKINE STORM SYNDROME | BUNNER, BRIDGET E | 1647 | §103§112Other | Final Rejection | 16d | Pending | Oct 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial